EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

Jilong Wang, Ning Lu, Zhuo Yan, Luyi Ye, Luyao Bai, Shanshan Yuan, Yuting Zhu, Yiru Xiong, Yongheng Bai, Yaping Chen, Junjie Deng

Advanced Science · 2026

DOI: 10.1002/advs.75406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jilong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, C…. Hauptthemen laut MEDLINE: Macrophages, Immunotherapy, Oncolytic Viruses, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Province Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, Zhejiang Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophage‐based immunotherapy holds great promise for solid tumors but is limited by impaired phagocytosis and unstable M1‐type polarization due to immunosuppressive tumor microenvironments. Here, we develop engineered macrophages by conjugating oncolytic adenovirus (OA)‐loaded zeolitic imidazolate framework‐8 (ZIF‐8) onto macrophage surfaces via bioorthogonal chemistry (ZIFOA‐M). This platform leverages localized viral delivery to selectively downregulate “don't eat me” signals (CD47 and CD24) on tumor cells, thereby restoring macrophage phagocytic capacity. Moreover, viral replication within tumors induces immunogenic cell death, releasing major damage‐associated molecular patterns (DAMPs) that sustain M1‐type polarization and promote durable antitumor immunity. ZIFOA‐M also enhances tumor antigen presentation, eliciting robust tumor‐specific T cell responses. Our strategy integrates phagocytosis restoration, microenvironment remodeling, and adaptive immune activation in a single, localized platform. ZIFOA‐M offers a complementary and translatable approach to overcome key barriers in macrophage‐based cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesImmunotherapyOncolytic VirusesNeoplasmsOncolytic VirotherapyAnimalsMiceHumansTumor MicroenvironmentAdenoviridae

Stichwörter der Autor:innen

Oncolytic adenovirusanti‐tumorarmored macrophageimmunotherapy

Autor:innen und Institutionen

  • Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Joint Centre of Translational Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
  • Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain, Health), Wenzhou, Zhejiang, China.
  • Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Province Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation
  • Zhejiang Provincial Department of Science and Technology
  • Wenzhou High Level Innovation Team Program
  • Scientific Research Project of Wenzhou Medical University
  • Huadong Medicine Joint Fund of Zhejiang Provincial Natural Science Foundation of China
  • Discipline Cluster of Oncology of Wenzhou Medical University in China

Zitieren

APA

Wang, J., Lu, N., Yan, Z., Ye, L., Bai, L., Yuan, S., Zhu, Y., Xiong, Y., Bai, Y., Chen, Y., & Deng, J. (2026). Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.75406

Vancouver

Wang J, Lu N, Yan Z, Ye L, Bai L, Yuan S, et al. Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy. Advanced Science. 2026. doi:10.1002/advs.75406

BibTeX
@article{Wang2026,
  author = {Wang, Jilong and Lu, Ning and Yan, Zhuo and Ye, Luyi and Bai, Luyao and Yuan, Shanshan and Zhu, Yuting and Xiong, Yiru and Bai, Yongheng and Chen, Yaping and Deng, Junjie},
  title = {Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.75406}
}
Kostenlos starten →